Expanding Public‐Private Collaborations to Enhance Cancer Drug Development: A Report of the Institute of Medicine's Workshop Series, “Implementing a National Cancer Clinical Trials System for the 21st Century”

• Published in: The oncologist (Dayton, Ohio) Vol. 19; no. 11; pp. 1179 - 1185
• Main Authors: Bertagnolli, Monica M., Canetta, Renzo, Nass, Sharyl J.
• Format: Journal Article
• Language: English
• Published: Durham, NC, USA AlphaMed Press 01-11-2014
• Subjects: Antineoplastic Agents; Biomedical Research - organization & administration; Biomedical Research - trends; Clinical trials; Clinical Trials as Topic; Drug development; Drug Discovery - organization & administration; Humans; Institute of Medicine; National Cancer Institute; National Cancer Institute (U.S.); New Drug Development and Clinical Pharmacology; Public-Private Sector Partnerships - organization & administration; Societies, Scientific; Translational Medical Research - organization & administration; Translational Medical Research - trends; United States; United States; Clinical trials; National Cancer Institute; Institute of Medicine; Drug development
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.2014-0240

Since their inception in the 1950s, the National Cancer Institute‐funded cancer cooperative groups have been important contributors to cancer clinical and translational research. In 2010, a committee appointed by the Institute of Medicine (IOM) of the National Academy of Sciences completed a consensus review on the status of the U.S. publicly funded cancer clinical trials system. This report identified a need to reinvigorate the cooperative groups and provided recommendations for improving their effectiveness. Follow‐up workshops to monitor progress were conducted by the IOM's National Cancer Policy Forum and the American Society of Clinical Oncology (ASCO) in 2011 and 2013. One of the key recommendations of the IOM report was a call for greater collaboration among stakeholders in cancer research. In particular, more active engagement and better alignment of incentives among the cooperative groups, the National Cancer Institute, the U.S. Food and Drug Administration, and the biopharmaceutical industry were identified as essential to achieving the promise of oncology drug development. This review, based on presentations and discussion during the IOM‐ASCO workshops, outlines the progress and remaining challenges of these collaborations.
This review, based on presentations and discussion during the Institute of Medicine and American Society of Clinical Oncology workshops, outlines the progress and challenges of collaborations among stakeholders in cancer research and drug development.